The VAD Journal: The journal of mechanical assisted circulation and heart failure

Brano Heart Failure Forum 2019 Conference Proceeding Paper

Advantages of bridging to durable left ventricular
assist device with the Impella 5.0
Manish K. Patel, MD

Citation: Patel M. Advantages
of Bridging to Durable Left
Ventricular Assist Device with
the Impella 5.0. The VAD
Journal. 2020; 6(2):e2020628.
https://doi.org/10.11589/vad/e
2020628
Editor-in-Chief: Maya Guglin,
University of Kentucky
Received: October 2, 2020
Accepted: December 3, 2020
Published Online: January 12,
2021
© 2021 The Author(s). This is an

open access article published
under the terms of the Creative
Commons AttributionNonCommercial 4.0 International
License
(https://creativecommons.org/lice
nses/by-nc/4.0/), which permits
unrestricted non-commercial use,
distribution, and reproduction in
any medium, provided that the
original author(s) and the
publication source are credited.

Department of Advanced Cardiopulmonary Therapies and Transplantation,
University of Texas Health Science Center at Houston, Houston TX
Corresponding author: manish.k.patel@uth.tmc.edu

Keywords: temporary circulatory support, left ventricular assist device,
cardiogenic shock

Abstract
The mainstay therapy for patients in critical cardiogenic shock (CS) is temporary
mechanical circulatory support. Although there is a trend toward use of durable
left ventricular assist devices (LVAD) in patients that are less ill, we present our
experience with using the Impella 5.0 (Abiomed) to illustrate the potential benefits
of supporting patients with critical CS before durable LVAD implantation. Since
2012, our use of the Impella has increased from 5 to 38 per year. Mortality is
highest early after LVAD implantation, but our long-term survival is better than data
reported to the INTERMACS registry. Use of an Impella 5.0 device as a bridge-todurable LVAD in patients with critical CS may offer long-term survival benefit.
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Summary of Presentation
Cardiogenic shock (CS) refractory to medical therapy is increasing in incidence
and is associated with an in-hospital mortality rate of nearly 50%.1 The mainstay
therapy for patients in critical CS is temporary circulatory support with devices
such as the intra-aortic balloon pump (IABP), percutaneous assist devices, or
veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Data from the
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)
show that fewer patients are implanted with durable devices who are in critical CS
(INTERMACS profile 1), whereas patients who are less-ill but declining or stable
with maximal medical therapy (INTERMACS profiles 2-3) are most commonly
implanted 2. Hence, there has been a trend toward increased use of short-term
circulatory support in the sickest patients as a bridge to either transplantation,
implantation of durable left ventricular assist device (LVAD), total artificial heart
(TAH), or other definitive therapy.3-5
At a large urban hospital’s advanced heart failure department, the percentage of
patients classified as INTERMACS profile 1 before LVAD implantation is
considerably higher than reported in the INTERMACS Registry (42% vs 14.3%);
however, the short-term survival of this single institution is nearly equivalent to the
INTERMACS population and the long-term survival is better (Figure 1).2 Use of
short-term circulatory support as a bridge-to-durable LVAD has allowed for better
patient selection and the optimization of patient’s condition before implantation.
The following case reports and overview of our experience using the Impella 5.0
(Abiomed, Danvers, MA) illustrate the potential benefits of supporting patients with
critical CS before durable LVAD implantation.

Figure 1. Patient survival from a large, urban hospital (Memorial Hermann
Hospital, Houston, TX; MHH) is compared to data from the Interagency Registry
for Mechanically Assisted Circulatory Support (INTERMACS).
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Patient 1
A 61-year-old Caucasian male with a history of ischemic heart failure, left
ventricular ejection fraction (LVEF) <20%, prior automatic implantable cardioverter
defibrillator (AICD), atrial fibrillation, hypertension, peripheral vascular disease,
type II diabetes, and chronic obstructive pulmonary disease (COPD) presented
with increasing lower extremity and scrotal edema. Further assessment revealed
severe malnutrition with deconditioning, uncontrolled type II diabetes (HbA1c =
8.8), a non-healing ulcer of the foot, severe peripheral vascular disease, COPD
with CO2 retention, and coronary artery disease not suitable for surgical repair.
Twelve days after admission, percutaneous coronary revascularization was
attempted, and an IABP was placed. After nine days of gradual deterioration, an
Impella 5.0 ventricular assist device was implanted via the axillary artery. The
patient’s condition was stabilized, and he underwent successful implantation of a
HeartMate 3 LVAD (Abbott, Chicago, IL) after 24 days of Impella support.
Patient 2
A 31-year-old African American male with non-ischemic cardiomyopathy, LVEF
<20%, AICD, hypertension, hyperlipidemia, hypothyroidism, obstructive sleep
apnea, and morbid obesity was transferred for management of decompensated
heart failure. Upon admission, the patient was in severe CS and was not able to
tolerate inotropic therapy. One day after admission, the patient was taken to the
operating room and experienced cardiac arrest requiring defibrillation, CPR, and
he was placed on extracorporeal membrane oxygenation (ECMO) support. An
Impella 5.0 was placed via the axillary artery which provided adequate support,
allowing ECMO removal and extubation. The patient was stabilized on Impella
support for 4 days when a HeartMate 3 LVAD was successfully implanted.

Summary of Experience
Temporary circulatory support at this instution has been provided by the Impella
2.5 and 5.0 devices, TandemHeart (LivaNova, USA), CentriMag (Abbott, Chicago,
IL), IABP, and/or ECMO (Figure 2). Since 2012, our use of the Impella has
increased from 5 to 38 per year. In our recent experience using the Impella 5.0 as
a bridge to durable LVAD, 17 devices have been implanted and 3 patients were
transferred to our institution with the device in place. In 7 cases of CS following
acute myocardial infarction, patients who were initially supported by Impella 2.5,
Impella CP, IABP, or ECMO were converted to support with the Impella 5.0
inserted via the axillary artery. Of the 9 patients who received Impella 5.0 support,
5 were bridged to a durable LVAD and 3 underwent a successful heart
transplantation.

Discussion
In spite of inotropic support, many patients with CS cannot be hemodynamically
stabilized and have refractory low-cardiac output. Long-term assist devices are an
expensive option, and their implantation is complicated by a high rate of right heart
failure and mortality. Bridging patients with temporary circulatory support is
intended to stabilize hemodynamics and improve end-organ function and may
improve survival. Also, surgical risk may be reduced, and more time is allowed for
complete evaluation of prognosis and therapy.
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Figure 2. Use of temporary circulatory support at Memorial Hermann Hospital from
2012-2018. Abbreviations: Tandem, TandemHeart; IABP, intra-aortic balloon
pump; ECMO, extracorporeal membrane oxygenation.

In general, patients requiring temporary circulatory support before durable LVAD
implantation are much sicker and experience a higher rate of adverse events and
mortality after LVAD implantation.6. In our experience, mortality is also highest
early after implantation, but our long-term survival is better than data reported to
the INTERMACS registry. Patients requiring ECMO have a very high mortality and
adverse event rates, likely due to the severity of illness on presentation and may
be classified as INTERMACS profile 0.6 Use of an Impella 5.0 device as a bridgeto-durable LVAD in patients classified as INTERMACS profile 1 may offer longterm survival benefit; however, further multi-center, prospective studies are
needed.
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